Novartis study to compare Femara with AstraZeneca’s Arimidex

Share this article:
Novartis said it has initiated a study to compare its breast cancer drug Femara (letrozole) with AstraZeneca’s best-selling Arimidex (anastrozole), The Wall Street Journal reported. Novartis said the study will look at 4,000 patients around the world. It is the first trial that will compare the two medicines in use after breast cancer surgery. Last year Femara totaled $536 million in sales, compared with around $1.18 billion for Arimidex. AstraZeneca called the study a marketing move. A spokesperson for AstraZeneca told the Journal that the trial would be open-label, meaning that both doctors and patients will know which drugs are being used, unlike clinical studies required to obtain regulatory approval. “There is no scientific rationale for doing this,” the spokesperson said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.